CD27L Antibody (BU69): sc-65271

CD27L Antibody (BU69) is a mouse monoclonal IgG1 antibody that detects CD27L in human samples through immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD27L, also known as CD27 ligand, plays a crucial role in the immune system by providing essential co-stimulatory signals that enhance T cell activation and proliferation. Anti-CD27L antibody (BU69) interacts specifically with the CD27 receptor on T and B lymphocytes, promoting their survival and differentiation. This interaction is vital for the development of effective immune responses, particularly in the context of adaptive immunity. CD27L (BU69) monoclonal antibody enables research into normal immune function and various diseases, including autoimmune disorders and cancers, where CD27L signaling pathways may be dysregulated. Understanding the dynamics of CD27L and its receptor can provide insights into therapeutic strategies aimed at modulating immune responses, making CD27L (BU69) antibody an invaluable tool for researchers studying these complex interactions in human health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD27L Antibody (BU69) References:

1. CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors.  |  Held-Feindt, J. and Mentlein, R. 2002. Int J Cancer. 98: 352-6. PMID: 11920585
2. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.  |  Wyzgol, A., et al. 2009. J Immunol. 183: 1851-61. PMID: 19596991
3. Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.  |  Pratt, D., et al. 2017. J Neuropathol Exp Neurol. 76: 697-708. PMID: 28789475
4. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.  |  Massard, C., et al. 2019. Cancer Chemother Pharmacol. 83: 1057-1063. PMID: 30915497
5. Exploring the therapeutic potential of endolysin CD27L_EAD against Clostridioides difficile infection.  |  Cho, Y., et al. 2024. Int J Antimicrob Agents. 64: 107222. PMID: 38810936
6. CD27-CD27 ligand/CD70 interactions enhance alloantigen-induced proliferation and cytolytic activity in CD8+ T lymphocytes.  |  Brown, GR., et al. 1995. J Immunol. 154: 3686-95. PMID: 7706711
7. Characterization of the human CD27 ligand, a novel member of the TNF gene family.  |  Hintzen, RQ., et al. 1994. J Immunol. 152: 1762-73. PMID: 8120385
8. Phenotype and function of human B cells expressing CD70 (CD27 ligand).  |  Lens, SM., et al. 1996. Eur J Immunol. 26: 2964-71. PMID: 8977292
9. CD70 (CD27 ligand) expression by synovial fluid CD4+ T lymphocytes in rheumatoid arthritis: comment on the article by Kohem et al.  |  Brugnoni, D., et al. 1997. Arthritis Rheum. 40: 1186-8. PMID: 9182939
10. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.  |  Couderc, B., et al. 1998. Cancer Gene Ther. 5: 163-75. PMID: 9622100

The preferred CD27L antibody is CD27L Antibody (G-7): sc-365539.